Publication

A novel AI imaging biomarker of tumour vascularity and heterogeneity radiomics to predict survival benefit of fruquintinib vs placebo in metastatic colorectal cancer (mCRC)

A novel artificial intelligence (AI) imaging biomarker of tumour vascularity and heterogeneity radiomics to predict survival benefit of fruquintinib vs placebo in metastatic colorectal cancer (mCRC), September 1, 2025

Read the full abstract HERE.

Colorrectal